PTC Therapeutics’ CEO Matthew Klein says the uncertainties of gene therapy development and commercialization have led to huge opportunity costs. After shelving PTC’s preclinical gene therapy programs, he is leveraging the company's diverse platforms and expanding its commercial efforts.
PTC Therapeutics, Inc.’s CEO Matthew Klein “is thinking about focus.”
Klein recently discontinued the company’s preclinical gene therapy programs, reducing residual operating expenses by roughly 15% through the last three quarters of 2023. For PTC, that change is notable as...